Get started
Author

Taylor Koch

Observed institution: Loyola University Chicago
ORCID: 0009-0007-6504-5428
Observed ORCID: 0009-0007-6504-5428
OpenAlex ID: A5147203377
Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205
2026 · Rimas V. Lukas, Lijie Zhai, et al. · Clinical Cancer Research · 4
TMIC-67 Immunosuppressive IDO1 extracellularly accumulates in patient-resected glioblastoma IDHwt
2026 · Taylor Koch, Prashant Bommi, et al. · Neuro-Oncology
CNSC-39 Relationship between host age, the peritumoral brain, and overall survival in mice with intracranial human GBM
2026 · Manon Penco-Campillo, Yiyan Wu, et al. · Neuro-Oncology
Data Source1 from Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205
2026 · Rimas V. Lukas, Lijie Zhai, et al.
Supplementary Tables1 from Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205
2026 · Rimas V. Lukas, Lijie Zhai, et al.
Supplementary Figures1 from Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205
2026 · Rimas V. Lukas, Lijie Zhai, et al.
Data from Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205
2026 · Rimas V. Lukas, Lijie Zhai, et al.
Abstract 6826: Age-dependent neuro-immune changes in glioblastoma shape therapeutic response and reveal senescent microglia as a targetable vulnerability
2026 · Manon Penco-Campillo, Olaya de Dios, et al. · Cancer Research
Abstract A012: IDO1 PROTAC improves survival against human glioblastoma
2026 · Taylor Koch, Prashant V. Bommi, et al. · Cancer Research
Works count: 9
Citation count: 4
H-index: 1
I10-index:
Year
Topic
Type